TACE versus TAE as therapy for hepatocellular carcinoma

References

• Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med.340(10), 745–750 (1999).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362(9399), 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Doyon D, Mouzon A, Jourde AM et al. [Hepatic, arterial embolization in patients with malignant liver tumours (author’s transl)]. Ann. Radiol. (Paris)17(6), 593–603 (1974).
   PubMedGoogle Scholar
• Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology35(5), 1164–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology224(1), 47–54 (2002).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology37(2), 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol.30(1), 6–25 (2007).
   PubMed Web of Science ®Google Scholar
• Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin. Liver Dis.6(3), 259–266 (1986).
   PubMed Web of Science ®Google Scholar
• Chang JM, Tzeng WS, Pan HB et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer74(9), 2449–2453 (1994).
   PubMed Web of Science ®Google Scholar
• Kawai S, Okamura J, Ogawa M et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma – a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother. Pharmacol.31(Suppl.), S1–S6 (1992).
   Web of Science ®Google Scholar
• Graziadei IW, Sandmueller H, Waldenberger P et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl.9(6), 557–563 (2003).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl.10(2 Suppl. 1), S115–S120 (2004).
   PubMedGoogle Scholar
• Maeda S, Fujiyama S, Tanaka M et al. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol. Res.23(3), 202–210 (2002).
   PubMedGoogle Scholar
• Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-α therapy for highly advanced hepatocellular carcinoma. Hepatol. Res.37(Suppl. 2), S238–S250 (2007).
   PubMedGoogle Scholar
• Yu SC, Hui EP, Wong J et al. Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: Phase II study. J. Vasc. Interv. Radiol.19(1), 95–103 (2008).
   PubMedGoogle Scholar
• Lau WY, Lai EC. Treatment of unresectable hepatocellular carcinoma with transarterial radioembolization: iodine-131-lipiodol. ANZ J. Surg.78(5), 331–332 (2008).
   PubMedGoogle Scholar
• Gu T, Li CX, Feng Y et al. Trans-arterial gene therapy for hepatocellular carcinoma in a rabbit model. World J. Gastroenterol.13(14), 2113–2117 (2007).
   PubMedGoogle Scholar
• Lewis AL, Gonzalez MV, Lloyd AW et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol.17(2 Pt 1), 335–342 (2006).
   PubMed Web of Science ®Google Scholar
• Abe S, Otsuki M. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Curr. Med. Chem. Anticancer Agents2(6), 715–726 (2002).
   PubMedGoogle Scholar
• Kasugai H, Kojima J, Tatsuta M et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology97(4), 965–971 (1989).
   PubMed Web of Science ®Google Scholar
• Kawai S, Tani M, Okamura J et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin. Oncol.24(2 Suppl. 6), S6-38–S6-45 (1997).
   Google Scholar
• Watanabe S, Nishioka M, Ohta Y et al. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother. Pharmacol.33(Suppl.), S93–S96 (1994).
   PubMed Web of Science ®Google Scholar
• Ichida T, Kato M, Hayakawa A et al. Treatment of hepatocellular carcinoma with a CDDP–epirubicin–lipiodol suspension: a pilot clinico–pharmacological study. Cancer Chemother. Pharmacol.31(Suppl.), S51–S54 (1992).
   PubMed Web of Science ®Google Scholar
• Ono Y, Yoshimasu T, Ashikaga R et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am. J. Clin. Oncol.23(6), 564–568 (2000).
   PubMedGoogle Scholar
• Xiong ZP, Zhang YD, Huang F et al. [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi29(8), 623–625 (2007).
   PubMedGoogle Scholar
• Lu W, Li Y, He X et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology50(54), 2079–2083 (2003).
   PubMedGoogle Scholar
• Bhattacharya S, Novell JR, Winslet MC et al. Iodized oil in the treatment of hepatocellular carcinoma. Br. J. Surg.81(11), 1563–1571 (1994).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Koizumi S, Katagiri S et al. [Usefulness of hepatic arterial infusion chemotherapy using lecithin-added lipiodol emulsion in hepatocellular carcinoma]. Gan To Kagaku Ryoho34(9), 1433–1437 (2007).
   PubMedGoogle Scholar
• Kobayashi S, Narimatsu Y, Ogawa K et al. Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation. Cancer Chemother. Pharmacol.31(Suppl.), S45–S50 (1992).
   Google Scholar
• Johnson PJ, Kalayci C, Dobbs N et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J. Hepatol.13(1), 120–127 (1991).
   PubMed Web of Science ®Google Scholar
• Dodds HM, Walpole ET, Rivory LP et al. Disposition of epirubicin after intraarterial administration in lipiodol to patients with hepatocellular carcinoma. Ther. Drug. Monit.18(5), 537–543 (1996).
   PubMedGoogle Scholar
• Favoulet P, Cercueil JP, Faure P et al. Increased cytotoxicity and stability of lipiodol–pirarubicin emulsion compared to classical doxorubicin–lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs12(10), 801–806 (2001).
   PubMedGoogle Scholar
• Fujiyama S, Shibata J, Maeda S et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br. J. Cancer89(9), 1614–1619 (2003).
   PubMedGoogle Scholar
• Chen MS, Li JQ, Zhang YQ et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J. Gastroenterol.8(1), 74–78 (2002).
   PubMed Web of Science ®Google Scholar
• Matsuo N, Uchida H, Sakaguchi H et al. Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings. Semin. Oncol.24(2 Suppl. 6), S6-61–S6-70 (1997).
   Google Scholar
• Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics14(3), 623–643 (1994).
   PubMed Web of Science ®Google Scholar
• Chung JW. Transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatogastroenterology45(Suppl. 3), 1236–1241 (1998).
   PubMedGoogle Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology42(5), 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Doppman JL, Dunnick NR, Girton M et al. Bile duct cysts secondary to liver infarcts: report of a case and experimental production by small vessel hepatic artery occlusion. Radiology130(1), 1–5 (1979).
   PubMedGoogle Scholar
• Makuuchi M, Sukigara M, Mori T et al. Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology156(2), 331–334 (1985).
   PubMed Web of Science ®Google Scholar
• Nakamura H, Tanaka T, Hori S et al. Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology147(2), 401–405 (1983).
   PubMed Web of Science ®Google Scholar
• Sigurdson ER, Ridge JA, Daly JM. Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake. Arch. Surg.121(11), 1277–1281 (1986).
   PubMedGoogle Scholar
• Dakhil S, Ensminger W, Cho K et al. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer50(4), 631–635 (1982).
   PubMed Web of Science ®Google Scholar
• Forsberg JO. Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. Acta Chir. Scand.144(5), 275–281 (1978).
   PubMedGoogle Scholar
• Kirchhoff TD, Bleck JS, Dettmer A et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat. Dis. Int.6(3), 259–266 (2007).
   PubMed Web of Science ®Google Scholar
• Gunji T, Kawauchi N, Ohnishi S et al. Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. Hepatology15(2), 252–257 (1992).
   PubMed Web of Science ®Google Scholar
• Gunji T, Kawauchi N, Akahane M et al. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma. Int. J. Oncol.21(2), 427–432 (2002).
   PubMedGoogle Scholar
• Zheng C, Feng G, Liang H. Bletilla striata as a vascular embolizing agent in interventional treatment of primary hepatic carcinoma. Chin. Med. J. (Engl.)111(12), 1060–1063 (1998).
   PubMed Web of Science ®Google Scholar
• Brown DB, Pilgram TK, Darcy MD et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J. Vasc. Interv. Radiol.16(12), 1661–1666 (2005).
   PubMedGoogle Scholar
• Lewis AL, Gonzalez MV, Leppard SW et al. Doxorubicin eluting beads – 1: effects of drug loading on bead characteristics and drug distribution. J. Mater. Sci. Mater. Med.18(9), 1691–1699 (2007).
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol.46(3), 474–481 (2007).
   PubMed Web of Science ®Google Scholar
• Poon RT, Tso WK, Pang RW et al. A Phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol.5(9), 1100–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Del PP, Maddeo A, Zabbialini G et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads. J. Hepatol.47(1), 157–158 (2007).
   PubMedGoogle Scholar
• Malagari K, Chatzimichael K, Alexopoulou E et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc. Intervent. Radiol.31(2), 269–280 (2008).
   PubMed Web of Science ®Google Scholar
• Georgiades CS, Hong K, D’Angelo M et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J. Vasc. Interv. Radiol.16(12), 1653–1659 (2005).
   PubMed Web of Science ®Google Scholar
• Nicolini A, Fasani P, Manini MA et al. Transarterial embolization with microspheres in the treatment of monofocal HCC. Dig. Liver Dis. (2008) (Epub ahead of print).
   Google Scholar
• Rand T, Loewe C, Schoder M et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc. Intervent. Radiol.28(3), 313–318 (2005).
   PubMed Web of Science ®Google Scholar
• Amesur NB, Zajko AB, Carr BI. Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. Dig. Dis. Sci.53(5), 1400–1404 (2008).
   PubMed Web of Science ®Google Scholar
• Chung JW, Park JH, Han JK et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology198(1), 33–40 (1996).
   PubMed Web of Science ®Google Scholar
• Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol.5(7), 409–418 (2004).
   PubMed Web of Science ®Google Scholar
• Geschwind JF, Ramsey DE, Cleffken B et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc. Intervent. Radiol.26(2), 111–117 (2003).
   PubMed Web of Science ®Google Scholar
• Ernst O, Sergent G, Mizrahi D et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am. J. Roentgenol.172(1), 59–64 (1999).
   PubMed Web of Science ®Google Scholar
• Matsui O, Kadoya M, Yoshikawa J et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother. Pharmacol.33(Suppl.), S84–S88 (1994).
   Google Scholar
• Nishimine K, Uchida H, Matsuo N et al. Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother. Pharmacol.33(Suppl.), S60–S68 (1994).
   PubMed Web of Science ®Google Scholar
• Jaeger HJ, Mehring UM, Castaneda F et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc. Intervent. Radiol.19(6), 388–396 (1996).
   PubMedGoogle Scholar
• Lin DY, Liaw YF, Lee TY et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial. Gastroenterology94(2), 453–456 (1988).
   PubMed Web of Science ®Google Scholar
• Monna T, Kanno T, Marumo T et al. A comparison of transcatheter arterial embolization with one shot therapy for the patients with hepatic cell carcinoma. Gastroenterol. Jpn17(6), 542–549 (1982).
   PubMedGoogle Scholar
• Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology131(2), 461–469 (2006).
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Torashima M, Oguni T et al. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation. Abdom. Imaging18(4), 352–356 (1993).
   PubMedGoogle Scholar
• Marelli L, Shusang V, Senzolo M et al. Repeated courses of transarterial embolization with polyvinyl alcohol particles: ‘long life elixir’ in a cirrhotic patient with unresectable hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol.19(4), 329–332 (2007).
   PubMedGoogle Scholar
• Plentz RR, Lankisch TO, Basturk M et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J. Gastroenterol. Hepatol.20(7), 1134–1136 (2005).
   PubMed Web of Science ®Google Scholar
• Takayasu K, Shima Y, Muramatsu Y et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology163(2), 345–351 (1987).
   PubMed Web of Science ®Google Scholar
• Hatanaka Y, Yamashita Y, Takahashi M et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology195(3), 747–752 (1995).
   PubMed Web of Science ®Google Scholar
• Ramsey DE, Kernagis LY, Soulen MC et al. Chemoembolization of hepatocellular carcinoma. J. Vasc. Interv. Radiol.13(9 Pt 2), S211–S221 (2002).
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Ishii M, Ueno Y et al. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver19(1), 25–31 (1999).
   PubMedGoogle Scholar
• Liou TC, Shih SC, Kao CR et al. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J. Hepatol.23(5), 563–568 (1995).
   PubMedGoogle Scholar
• Louha M, Poussin K, Ganne N et al. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology26(4), 998–1005 (1997).
   PubMedGoogle Scholar
• Stigliano R, Marelli L, Yu D et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat. Rev.33(5), 437–447 (2007).
   PubMed Web of Science ®Google Scholar
• Ikeda K, Saitoh S, Koida I et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am. J. Clin. Oncol.18(3), 204–210 (1995).
   PubMed Web of Science ®Google Scholar
• Ikeda K, Saitoh S, Suzuki Y et al. A prospective randomized administration of 5´-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am. J. Clin. Oncol.20(2), 202–208 (1997).
   PubMed Web of Science ®Google Scholar
• Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer84(7), 886–891 (2001).
   PubMed Web of Science ®Google Scholar
• Yan JJ, Shen F, Wang K et al. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat. Dis. Int.1(2), 183–186 (2002).
   PubMedGoogle Scholar
• Stefanini GF, Foschi FG, Castelli E et al. α-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology45(19), 209–215 (1998).
   PubMed Web of Science ®Google Scholar
• Williams KJ, Telfer BA, Xenaki D et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol.75(1), 89–98 (2005).
   PubMed Web of Science ®Google Scholar
• Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol.22(8), 1178–1182 (2007).
   PubMed Web of Science ®Google Scholar
• von MZ, Cramer T, Hocker M et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut48(1), 87–96 (2001).
   PubMedGoogle Scholar
• Xiong ZP, Yang SR, Liang ZY et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int.3(3), 386–390 (2004).
   PubMedGoogle Scholar
• Jiang H, Meng Q, Tan H et al. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int. J. Cancer121(2), 416–424 (2007).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Yang WT, Johnson PJ. Monitoring response to treatment in liver tumours. Baillieres Best Pract. Res. Clin. Gastroenterol.13(4), 637–654 (1999).
   PubMedGoogle Scholar
• Filmus J, Capurro M. Glypican-3 and α-fetoprotein as diagnostic tests for hepatocellular carcinoma. Mol. Diagn.8(4), 207–212 (2004).
   PubMedGoogle Scholar
• Hosoki T, Yosioka Y, Matsubara T et al. Power Doppler sonography of hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Assessment of the therapeutic effect. Acta Radiol.40(6), 639–643 (1999).
   PubMed Web of Science ®Google Scholar
• Ito K, Honjo K, Fujita T et al. Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology. J. Comput. Assist. Tomogr.19(2), 198–203 (1995).
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Yoshimatsu S, Sumi M et al. Dynamic MR imaging of hepatoma treated by transcatheter arterial embolization therapy. Assessment of treatment effect. Acta Radiol.34(3), 303–308 (1993).
   PubMedGoogle Scholar
• Miraglia R, Pietrosi G, Maruzzelli L et al. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J. Gastroenterol.13(21), 2952–2955 (2007).
   PubMed Web of Science ®Google Scholar
• Miraglia R, Pietrosi G, Maruzzelli L et al. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J. Gastroenterol.13(45), 6022–6026 (2007).
   PubMedGoogle Scholar
• Tezuka M, Hayashi K, Kubota K et al. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig. Dis. Sci.52(3), 783–788 (2007).
   PubMed Web of Science ®Google Scholar
• Kubota K, Ina H, Okada Y et al. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig. Dis. Sci.48(3), 581–586 (2003).
   PubMed Web of Science ®Google Scholar
• Molinari M, Kachura JR, Dixon E et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin. Oncol. (R. Coll. Radiol.)18(9), 684–692 (2006).
   PubMedGoogle Scholar
• Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol.8(2), 117–136 (1997).
   PubMed Web of Science ®Google Scholar
• Trevisani F, De Notariis S, Rossi C et al. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J. Clin. Gastroenterol.32(5), 383–389 (2001).
   PubMedGoogle Scholar
• Trinchet JC, Ganne-Carrie N, Beaugrand M. Intra-arterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology45(Suppl. 3), 1242–1247 (1998).
   PubMedGoogle Scholar
• Geschwind JF, Ramsey DE, Choti MA et al. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am. J. Clin. Oncol.26(4), 344–349 (2003).
   PubMedGoogle Scholar
• Shen H, Agarwal D, Qi R et al. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment. Pharmacol. Ther.26(3), 393–400 (2007).
   PubMed Web of Science ®Google Scholar
• Dvorchik I, Carr BI. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. Cancer Detect. Prev.31(2), 154–160 (2007).
   PubMedGoogle Scholar
• Cho YK, Chung JW, Kim JK et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer112(2), 352–361 (2008).
   PubMedGoogle Scholar
• Brown DB, Chapman WC, Cook RD et al. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am. J. Roentgenol.190(3), 608–615 (2008).
   PubMedGoogle Scholar
• Herber SC, Otto G, Schneider J et al. Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am. J. Roentgenol.190(4), 1035–1042 (2008).
   PubMedGoogle Scholar
• Lewis AL, Taylor RR, Hall B et al. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J. Vasc. Interv. Radiol.17(8), 1335–1343 (2006).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ikeda M, Okusaka T et al. A Phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin–lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Cancer Chemother. Pharmacol.61(4), 683–688 (2008).
   PubMedGoogle Scholar
• Castells A, Bruix J, Ayuso C et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J. Hepatol.22(4), 410–415 (1995).
   PubMed Web of Science ®Google Scholar
• Bismuth H, Morino M, Sherlock D et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am. J. Surg.163(4), 387–394 (1992).
   PubMedGoogle Scholar
• Hwang TL, Chen MF, Lee TY et al. Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization. Arch. Surg.122(7), 756–759 (1987).
   PubMedGoogle Scholar
• Takenaka K, Yoshida K, Nishizaki T et al. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am. J. Surg.169(4), 400–404 (1995).
   PubMed Web of Science ®Google Scholar
• Paye F, Farges O, Dahmane M et al. Cytolysis following chemoembolization for hepatocellular carcinoma. Br. J. Surg.86(2), 176–180 (1999).
   PubMedGoogle Scholar
• Wigmore SJ, Redhead DN, Thomson BN et al. Postchemoembolisation syndrome – tumour necrosis or hepatocyte injury? Br. J. Cancer89(8), 1423–1427 (2003).
   PubMedGoogle Scholar
• Wang ZX, Liu SL, Sun CH et al. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia. World J. Gastroenterol.14(6), 931–935 (2008).
   PubMedGoogle Scholar
• Chan AO, Yuen MF, Hui CK et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer94(6), 1747–1752 (2002).
   PubMed Web of Science ®Google Scholar
• Lu W, Li YH, Yu ZJ et al. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology54(77), 1499–1502 (2007).
   PubMed Web of Science ®Google Scholar
• Feng YL, Ling CQ, Chen Z et al. [Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient]. Zhonghua Zhong Liu Za Zhi28(11), 844–847 (2006).
   PubMedGoogle Scholar
• Tarazov PG, Polysalov VN, Prozorovskij KV et al. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol.41(2), 156–160 (2000).
   PubMed Web of Science ®Google Scholar
• Chen C, Chen PJ, Yang PM et al. Clinical and microbiological features of liver abscess after transarterial embolization for hepatocellular carcinoma. Am. J. Gastroenterol.92(12), 2257–2259 (1997).
   PubMedGoogle Scholar
• Cohen SE, Safadi R, Verstandig A et al. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig. Dis. Sci.42(5), 938–943 (1997).
   PubMedGoogle Scholar
• Kim HK, Chung YH, Song BC et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J. Clin. Gastroenterol.32(5), 423–427 (2001).
   PubMedGoogle Scholar
• Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J. Gastroenterol.11(10), 1554–1557 (2005).
   PubMedGoogle Scholar
• Morante A, Romano M, Cuomo A et al. Massive gastric ulceration after transarterial chemoembolization for hepatocellular carcinoma. Gastrointest. Endosc.63(4), 718–720 (2006).
   PubMedGoogle Scholar
• Huo TI, Wu JC, Lee PC et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int.24(3), 210–215 (2004).
   PubMedGoogle Scholar
• Guevara M, Fernandez-Esparrach G, Alessandria C et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology40(3), 646–651 (2004).
   PubMed Web of Science ®Google Scholar
• Birck R, Krzossok S, Markowetz F et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet362(9384), 598–603 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly AM, Dwamena B, Cronin P et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann. Intern. Med.148(4), 284–294 (2008).
   PubMed Web of Science ®Google Scholar
• Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc. Interv.64(4), 471–479 (2005).
   PubMedGoogle Scholar
• Liu R, Nair D, Ix J et al.N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J. Gen. Intern. Med.20(2), 193–200 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzales DA, Norsworthy KJ, Kern SJ et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med.5, 32 (2007).
   PubMedGoogle Scholar
• Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med.2, 38 (2004).
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, McAlister FA, Manns BJ et al. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch. Intern. Med.166(2), 161–166 (2006).
   PubMed Web of Science ®Google Scholar
• Nallamothu BK, Shojania KG, Saint S et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am. J. Med.117(12), 938–947 (2004).
   PubMed Web of Science ®Google Scholar
• Pannu N, Manns B, Lee H et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int.65(4), 1366–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Shusang V, Marelli L et al. Review article: renal function assessment in cirrhosis – difficulties and alternative measurements. Aliment. Pharmacol. Ther.26(7), 969–978 (2007).
   PubMed Web of Science ®Google Scholar
• Noguera JJ, Martinez-Cuesta A, Sangro B et al. [Fatal pulmonary embolism after embolization of a hepatocellular carcinoma using microspheres.]. Radiologia50(3), 248–250 (2008).
   PubMedGoogle Scholar
• Czauderna P, Zbrzezniak G, Narozanski W et al. Pulmonary embolism: a fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma. J. Pediatr. Surg.40(10), 1647–1650 (2005).
   PubMedGoogle Scholar
• Yoo KM, Yoo BG, Kim KS et al. Cerebral lipiodol embolism during transcatheter arterial chemoembolization. Neurology63(1), 181–183 (2004).
   PubMedGoogle Scholar
• Buscarini L, Buscarini E, Di Stasi M et al. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall. Med.20(2), 47–53 (1999).
   PubMed Web of Science ®Google Scholar
• Seki T, Tamai T, Nakagawa T et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer89(6), 1245–1251 (2000).
   PubMed Web of Science ®Google Scholar
• Yamakado K, Nakatsuka A, Akeboshi M et al. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: short-term recurrences and survival. Oncol. Rep.11(1), 105–109 (2004).
   PubMed Web of Science ®Google Scholar
• Veltri A, Moretto P, Doriguzzi A et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur. Radiol.16(3), 661–669 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng BQ, Jia CQ, Liu CT et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA299(14), 1669–1677 (2008).
   PubMed Web of Science ®Google Scholar
• Yamagiwa K, Shiraki K, Yamakado K et al. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J. Gastroenterol. Hepatol.23(3), 482–490 (2008).
   PubMedGoogle Scholar
• Yamakado K, Nakatsuka A, Takaki H et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology247(1), 260–266 (2008).
   PubMed Web of Science ®Google Scholar
• Takaki H, Yamakado K, Nakatsuka A et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression. J. Vasc. Interv. Radiol.18(7), 856–861 (2007).
   PubMed Web of Science ®Google Scholar
• Koda M, Ueki M, Maeda Y et al. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol. Res.29(1), 18–23 (2004).
   PubMedGoogle Scholar
• Bartolozzi C, Lencioni R, Caramella D et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology197(3), 812–818 (1995).
   PubMed Web of Science ®Google Scholar
• Koda M, Murawaki Y, Mitsuda A et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer92(6), 1516–1524 (2001).
   PubMed Web of Science ®Google Scholar
• Dettmer A, Kirchhoff TD, Gebel M et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J. Gastroenterol.12(23), 3707–3715 (2006).
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat. Rev.32(8), 594–606 (2006).
   PubMedGoogle Scholar
• Akamatsu M, Yoshida H, Obi S et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int.24(6), 625–629 (2004).
   PubMed Web of Science ®Google Scholar
• Liao GS, Yu CY, Shih ML et al. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. Eur. J. Surg. Oncol.34(1), 61–66 (2008).
   PubMedGoogle Scholar
• Maluccio M, Covey AM, Gandhi R et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J. Vasc. Interv. Radiol.16(7), 955–961 (2005).
   PubMed Web of Science ®Google Scholar
• Chan ES, Chow PK, Tai B et al. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst. Rev. (2), CD001199 (2000).
   Google Scholar
• Schwartz JD, Schwartz M, Mandeli J et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol.3(10), 593–603 (2002).
   PubMedGoogle Scholar
• Wu CC, Ho YZ, Ho WL et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br. J. Surg.82(1), 122–126 (1995).
   PubMed Web of Science ®Google Scholar
• Li Q, Wang J, Sun Y et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig. Surg.23(4), 235–240 (2006).
   PubMed Web of Science ®Google Scholar
• Li Q, Wang J, Sun Y et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis – a randomized study. World J. Surg.30(11), 2004–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med.334(11), 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• Ravaioli M, Grazi GL, Ercolani G et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation78(12), 1780–1786 (2004).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ina H, Tezuka M et al. Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients. Cardiovasc. Intervent. Radiol.30(6), 1144–1155 (2007).
   PubMedGoogle Scholar
• Roayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann. Surg.235(4), 533–539 (2002).
   PubMed Web of Science ®Google Scholar
• Majno P, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials? Liver Transpl.13(11 Suppl. 2), S27–S35 (2007).
   Google Scholar
• Brown DB, Geschwind JF, Soulen MC et al. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J. Vasc. Interv. Radiol.17(2 Pt 1), 217–223 (2006).
   PubMed Web of Science ®Google Scholar
• Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl.11(7), 767–775 (2005).
   PubMed Web of Science ®Google Scholar
• Majno PE, Adam R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann. Surg.226(6), 688–701 (1997).
   PubMed Web of Science ®Google Scholar
• Oldhafer KJ, Chavan A, Fruhauf NR et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J. Hepatol.29(6), 953–959 (1998).
   PubMed Web of Science ®Google Scholar
• Perez SB, Meneu JC, Moreno E et al. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am. J. Surg.190(3), 383–387 (2005).
   PubMed Web of Science ®Google Scholar
• Yao FY, Kinkhabwala M, LaBerge JM et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am. J. Transplant.5(4 Pt 1), 795–804 (2005).
   PubMed Web of Science ®Google Scholar
• Dharancy S, Boitard J, Decaens T et al. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case–control study. Liver Transpl.13(5), 665–671 (2007).
   PubMedGoogle Scholar
• Lesurtel M, Mullhaupt B, Pestalozzi BC et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am. J. Transplant.6(11), 2644–2650 (2006).
   PubMed Web of Science ®Google Scholar
• Richard HM III, Silberzweig JE, Mitty HA et al. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology214(3), 775–779 (2000).
   PubMedGoogle Scholar
• Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl.11(12), 1505–1514 (2005).
   PubMed Web of Science ®Google Scholar
• Grasso A, Stigliano R, Morisco F et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation81(11), 1532–1541 (2006).
   PubMed Web of Science ®Google Scholar